» Articles » PMID: 21556552

Expression and Tyrosine Phosphorylation of Phosphatidyl-inositol-3 Kinase in Human Gastric-cancer Cells - Its Correlation with Cell-growth

Overview
Journal Int J Oncol
Specialty Oncology
Date 2011 May 11
PMID 21556552
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

To reveal the signaling pathway leading to oncogenecity of human cancer cells, we examined the expression and tyrosine-phosphorylation of phosphatidylinositol (PI)-3 kinase in cancer cell lines. Of the 14 cell lines examined, two poorly differentiated human gastric cancer cell lines, NUGC-4 and MKN-45, which were previously found to have aberrant elevation of tyrosine phosphorylation showed elevated levels of PI-3 kinase 85-kDa subunit expression. In these cells, tyrosine-phosphorylation and overall activity of PI-3 kinase were apparently elevated, compared with normal human fibroblasts and another well differentiated gastric cancer cell line, MKN-28. Treatment of these cells with tyrosine kinase inhibitor, genistein, strongly suppressed the PI-3 kinase activity. Furthermore, wortmannin, a potent inhibitor of PI-3 kinase, strongly suppressed the growth of these gastric cancer cells. These results suggest that the growth signaling via tyrosine phosphorylation is required for the activation of PI-3 kinase in NUGC4 and MKN-45, and that this activation plays an important role in oncogenic growth of these cells. However, these two cell lines showed different responses of PI-3 kinase to acid-treatment and tyrosine kinase inhibitors. In MKN-45, activation of PI-3 kinase appeared to be constitutive, and could be relevant to the oncogenic nature of the cell line.

Citing Articles

The Preparation of Gen-NH-MCM-41@SA Nanoparticles and Their Anti-Rotavirus Effects.

Song L, Chen J, Feng Y, Zhou Y, Li F, Dai G Pharmaceutics. 2022; 14(7).

PMID: 35890233 PMC: 9318718. DOI: 10.3390/pharmaceutics14071337.


Tumor cells express FcgammaRI which contributes to tumor cell growth and a metastatic phenotype.

Nelson M, Nyhus J, Oravecz-Wilson K Neoplasia. 2001; 3(2):115-24.

PMID: 11420747 PMC: 1505421. DOI: 10.1038/sj.neo.7900140.